TD-9855
0145
Phase 2 small_molecule completed
Quick answer
TD-9855 for Neurogenic Orthostatic Hypotension is a Phase 2 program (small_molecule) at Theravance Biopharma with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Theravance Biopharma
- Indication
- Neurogenic Orthostatic Hypotension
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed